pharmaceutical company

Scilex subsidiaries sell ACEA Pharma to Phoenix Asia for $1B in stock; retain 82% ownership post-Nasdaq listing in Q2 2026.

Pacira CFO sold $326K in stock via pre-planned trading arrangement before Q1 earnings beat, with shares appreciating 12% in April.

Immutep's $IMMP stock crashed 82.6% after discontinuing Phase III trial for lead drug candidate. Rosen Law Firm investigating potential securities violations and class action claims.

Inhibikase Therapeutics grants 685,718 stock options at $1.68/share to five new hires under Nasdaq inducement plan with ten-year terms.

Robbins LLP files class action against $SLNO over safety concerns regarding its Prader-Willi syndrome drug, following critical exposé and patient death disclosure.

ANI Pharma posts record $883M revenue (up 44% YoY) with rare disease growth driving performance; insider sells 4,772 shares amid $1B+ 2026 guidance.

SIGA Technologies declares $0.60 special cash dividend payable April 23, 2026, matching prior-year distribution and reflecting strong balance sheet.

XORTX shareholders approved a 5-to-1 share consolidation to maintain NASDAQ compliance, reducing shares from 6.96M to 1.39M ahead of April 2026 deadline.

Maze Therapeutics president Harold Bernstein sold all 30,000 shares for $1.51M via pre-arranged trading plan, weeks before Q4 earnings report.

Aquestive Therapeutics appoints Day Pitney partner Thomas Zalewski as Chief Legal Officer and Chief Compliance Officer, with Lori Braender transitioning to Corporate Secretary after eight years.

XORTX Therapeutics secures ISS endorsement for share consolidation, with proxy advisor backing March 2026 shareholder vote. ISS cited no direct shareholder value impact while noting improved financing prospects.

Robbins LLP launches class action against $SLNO over alleged investor deception regarding DCCR drug safety and efficacy for Prader-Willi syndrome treatment.

Amarin's sole drug Vascepa faces generic competition, causing revenue to plummet 36% to $183 million in 2025, raising serious concerns about the company's single-product vulnerability.

Viatris reaffirms $0.48 annual dividend per share for 2026, declaring $0.12 quarterly payout. Marks sixth consecutive year of consistent shareholder distributions.

Aquestive Therapeutics will present at four major healthcare investor conferences in March 2026, updating investors on its clinical pipeline and strategic initiatives.